Frameworks for Digital Advertising
Standards in Medicine.

Poland · Advertising framework

Radio spots and spoken promotions for prescription medicines in Poland

General market orientation, not campaign clearance. Research scope and dates

Key restrictions and conditions

Public advertising of prescription medicines is prohibited

Legal requirement — paraphrased

Do not plan a public prescription-medicine promotion in this channel. A consented mailing or a social-media age gate does not turn recipients into authorised healthcare professionals.

The statutory vaccination exception needs a separate assessment against the GIS vaccination communication. Professional promotion requires a genuinely restricted route and its own information requirements.

Sources: Pharmaceutical Law — consolidated text, Dz.U. 2026 item 612 · Article 57; advertising regulation section 12

First decide whether the message is medicine advertising

Legal requirement — paraphrased

Promotion intended to increase prescribing, supply, sale or consumption falls within the medicine-advertising regime. Unbranded disease education is excluded only if it makes no even indirect reference to medicines. Advertising must be conducted by, or commissioned by, the marketing-authorisation holder.

Sources: Pharmaceutical Law — consolidated text, Dz.U. 2026 item 612 · Articles 52 and 60

Product and service rules

Use authorised, balanced medicine information

Legal requirement — paraphrased

Do not advertise unauthorised medicines or claims inconsistent with the SmPC. Public advertising cannot target children or use celebrity, scientist or medical/pharmacy-professional presentation or recommendations. No guaranteed cure, absence-of-side-effects or natural-means-safe claims; no purchasing rewards.

Sources: Pharmaceutical Law — consolidated text, Dz.U. 2026 item 612; GIF — Advertising medicinal products · Articles 53, 55–57

Professional promotion is a separate restricted route

Legal requirement — paraphrased

Applies when: The recipients are eligible professionals and distribution is genuinely restricted.

If this channel is genuinely restricted to eligible professionals, use the professional-advertising regime, including SmPC-based information, prescribing category, relevant reimbursement information and dated supporting documentation. Do not make the material publicly accessible merely by labelling it professional.

Since 22 July 2026, section 12(4a) allows the specified professional information to be supplied electronically or through a QR/Data Matrix code or web address pointing to the responsible advertiser's site/platform. This is not an exemption for public consumer advertisements.

Sources: Medicine advertising regulation — consolidated text, Dz.U. 2023 item 1648; Medicine advertising amendment — Dz.U. 2026 item 910 · Section 12, including new paragraph 4a

Channel rules

Make the overall message truthful and commercially identifiable

Legal requirement — paraphrased

Misleading claims, material omissions, hidden commercial intent and aggressive consumer marketing are prohibited. Assess visuals, comparisons, qualifications and the impression on vulnerable consumers. Do not falsely claim that a product cures illness.

Editorial control: retain substantiation before publication, remove fabricated urgency or authority badges, and check that qualifications do not contradict the headline. Paying to publish apparently independent advice must not conceal its commercial nature.

Sources: Act on Counteracting Unfair Market Practices — consolidated text, Dz.U. 2023 item 845 · Articles 4–9; Article 7 hidden advertising and false cure claims

Check price reductions only after establishing that promotion is lawful

Legal requirement — paraphrased

Where an advertisement announces a reduction for a good or service, state the relevant lowest price from the preceding 30 days alongside the reduced price. For a shorter selling history, use the lowest price since sales began; special rules apply to rapidly perishable goods.

This consumer-information rule does not permit a discount or purchasing incentive prohibited by medicine or service rules. As an editorial check, make the total scope and extra charges clear.

Sources: UOKiK — Information about price reductions · Price Information Act Article 4 as explained by UOKiK

Keep reviews genuine and explain verification

Legal requirement — paraphrased

Do not publish, commission or distort false consumer recommendations. If making consumer reviews available, explain whether and how their origin is verified. Do not claim authentic-user verification without reasonable, proportionate checks.

Selecting a patient or customer story for advertising also requires checking the sector's claims and endorsement restrictions. A genuine testimonial can still contain an unlawful health claim.

Sources: UOKiK — False reviews? Stop!; Act on Counteracting Unfair Market Practices — consolidated text, Dz.U. 2023 item 845 · Unfair-practices Act Articles 6–7; UOKiK reviews guidance

Broadcast advertising adds separation, sponsorship and placement rules

Legal requirement — paraphrased

Commercial communications must be recognisable; hidden or subliminal advertising is prohibited. Advertising of healthcare services available exclusively on a doctor's referral is prohibited in the broadcasting regime. Product and provider restrictions apply in addition.

Sponsorship and product placement have separate conditions and cannot be used to bypass prohibited advertising. Have the broadcaster classify the execution and check the applicable restrictions, rather than treating a sponsorship ident as a normal ad slot.

Sources: Broadcasting Act — consolidated text, Dz.U. 2022 item 1722 · Articles 16, 16b–16c, 17 and 17a

Allow enough airtime for required spoken content

Editorial recommendation

Medicine and device warnings use different prescribed lengths; apply the relevant sector module rather than a universal health disclaimer. Include required product information clearly and assess the full voiceover, endorsement and sponsor treatment.

Recommended production check: time the final recording, listen for clarity at ordinary playback speed, and remove claims that become misleading without the visuals used in another version of the campaign.

Sources: Medicine advertising regulation — consolidated text, Dz.U. 2023 item 1648; Medical-device advertising regulation — Dz.U. 2023 item 817 · Medicine regulation section 8; device regulation section 3

Campaign workflow

Keep one campaign evidence and approval record

Editorial recommendation

Recommended workflow: record the exact offer and legal classification, advertiser, selected channel and creative formats; list permitted claims and evidence; review the Polish execution and destination; record sign-off, publication and corrections.

Keep the source date with the rule. Recheck legislation flagged as changing, especially pharmacy advertising. Preserve statutory archive periods where they apply; this suggested general workflow does not create a universal retention period.

Sources: URPL — Advertising medical devices; Sejm official API — Pharmacy advertising amendment, process 3002 · Specific retention and legislative-watch sources; workflow is editorial

Pre-publication checklist

  • Stop public Rx promotion; document any claimed statutory exception before developing creative.
  • Verify recipient eligibility and access restrictions before treating a placement as professional promotion.
  • Record the category gate before reviewing the channel.
  • Approve the final creative, disclosure, targeting and landing page together.
  • Assign an owner for corrections, expiry of claims and legislative updates.

Scope and unresolved questions

  • Product authorisations, intended users, approved documentation and final Polish creative must be checked for the actual offer. Veterinary products, controlled substances, vaccine exceptions and specialist product subtypes are not separately cleared by this category-level guide.
  • Confirm the service's legal classification, broadcaster jurisdiction and booking format. Cross-border broadcasts, on-demand services, sponsorship and product placement can need additional analysis.
Research scope, introduction and dates

For prescription medicines in radio spots in Poland, the first question is whether the message reaches the public or a genuinely restricted professional audience. Start with the advertising prohibition and any applicable exception before considering the creative.

A radio spot must communicate its meaning without supporting visuals. Listen to the final voiceover at ordinary playback speed and allow enough airtime for the information and any warning applicable to the advertised offer.

Sources checked 2026-10-24 · Editorial research · Legal review pending

General market orientation, not legal, regulatory or medical advice, a complete compliance plan or clearance of an advertisement. Actual requirements depend on the specific offer and campaign.

Coverage: Source-checked editorial research for all listed categories; campaign-specific legal review pending.

Resolve product and service restrictions before choosing a channel

Editorial overview

A platform label, newsletter consent, an advertising warning or a publisher's acceptance does not create permission to advertise. Apply the selected product/service gate first; if public promotion is prohibited, use this guide to identify the restriction and alternatives for specialist review.

This English guide describes Polish requirements. Required Polish warning text and locally understandable disclosure remain necessary where the law requires them.

Sources: Pharmaceutical Law — consolidated text, Dz.U. 2026 item 612; Healthcare Activity Act — consolidated text, Dz.U. 2026 item 156; Medical Devices Act — consolidated working text based on Dz.U. 2024 item 1620 · Product/service rules referenced in matching modules

Your next step: choose a local partner

Use this framework to brief qualified local legal and regulatory specialists. Ask them to verify current requirements and assess your specific product, service and campaign before acting.

Sources

  1. Pharmaceutical Law — consolidated text, Dz.U. 2026 item 612

    Polish Parliament · legislation · checked 2026-10-24

    Consolidation reflects 8 April 2026. Later amendments exist; pharmacy advertising must also be read with the CJEU judgment and the October 2026 legislative tracker in the pharmacy framework. This is a targeted advertising review, not an audit of the entire Act.

  2. Healthcare Activity Act — consolidated text, Dz.U. 2026 item 156

    Polish Parliament · legislation · checked 2026-10-24

    Public information must not have advertising characteristics. Information supplied at a patient's request under paragraph 2 is a different context.

  3. Medical Devices Act — consolidated working text based on Dz.U. 2024 item 1620

    Polish Parliament · legislation · checked 2026-10-24

    The inspected PDF is dated 19 November 2024. Advertising provisions were cross-checked against the current URPL advertising overview; recheck amendments before campaign sign-off.

  4. GIF — Advertising medicinal products

    Chief Pharmaceutical Inspectorate, Poland · regulator guidance · checked 2026-10-24

    The warning quoted on this older overview is superseded; use the medicine advertising regulation for warnings.

  5. Medicine advertising regulation — consolidated text, Dz.U. 2023 item 1648

    Minister of Health, Poland · legislation · checked 2026-10-25

    Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.

  6. Medicine advertising amendment — Dz.U. 2026 item 910

    Minister of Health, Poland · legislation · checked 2026-10-24

    Adds electronic/QR delivery of required information in professional advertising. Does not remove public-advertising warnings or relax the public Rx ban.

  7. Act on Counteracting Unfair Market Practices — consolidated text, Dz.U. 2023 item 845

    Polish Parliament · legislation · checked 2026-10-24

  8. UOKiK — Information about price reductions

    Office of Competition and Consumer Protection, Poland · regulator guidance · checked 2026-10-24

  9. UOKiK — False reviews? Stop!

    Office of Competition and Consumer Protection, Poland · regulator guidance · checked 2026-10-24

    The 30 July 2024 announcement also describes enforcement decisions; their subsequent appeal status is not asserted here.

  10. Broadcasting Act — consolidated text, Dz.U. 2022 item 1722

    Polish Parliament · legislation · checked 2026-10-24

    Later amendments exist. The cited advertising provisions were inspected; do not infer that an ordinary social account is automatically an on-demand audiovisual media service.

  11. Medical-device advertising regulation — Dz.U. 2023 item 817

    Minister of Health, Poland · legislation · checked 2026-10-25

    Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.

  12. URPL — Advertising medical devices

    URPL, Poland · regulator guidance · checked 2026-10-24

  13. Sejm official API — Pharmacy advertising amendment, process 3002

    Polish Parliament · legislative tracker · checked 2026-10-25

    Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.

From framework to action

Local expertise in Poland

Find support with medical and health marketing, marketing and sales advice, or organizing your business and coordinating projects in Poland.

Medical & health marketing

No partners listed in this category yet.

Marketing & sales advisory

Marketing & sales advisory

Casbeg

Marketing and sales consulting for businesses in Poland: strategy, commercial processes, lead generation and CRM implementation.

View partner profile

Business & project coordination

No partners listed in this category yet.

Browse partners in Poland

Join the local partner directory

Would you like your company to be listed?

Talk to us about the terms of a listing. Leave your details and we will get in touch.

Publicity@fdasm.com

Contact details for a partner listing enquiry

We use your details to respond to your enquiry and discuss a listing. Submitting the form does not automatically add your company to the directory. Read our Privacy & cookies policy. Privacy contact: Publicity@fdasm.com.